即用型p-Branch开窗支架的多中心前瞻性单中心临床试验结果
该研究汇总了美国与欧洲四个单中心前瞻性研究,评估即用型Zenith p-Branch开窗支架治疗近肾腹主动脉瘤。共76例患者(65例择期,11例急诊),装置全部成功释放,无30天死亡,随访25±13个月无破裂或开放转归。肾动脉闭塞发生8例(11%),总体肾功能不全发生率7%(5/76)。
要点
- 即用型p-Branch支架治疗近肾腹主动脉瘤技术上可行且安全。
- 肾动脉闭塞发生率为11%(8/76),其中63%被认为与手术相关。
- 需要长期随访评估疗效与耐久性并完善适应证。
核心结论
- 早期结果表明,使用Zenith p-Branch装置是可行且安全的,但需长期随访评估疗效与耐久性并完善适应证。
研究设计与样本
- 汇总美国与欧洲四个单中心前瞻性研究数据,共76例近肾腹主动脉瘤患者(82%男性,平均年龄72岁,65例择期、11例急诊)。
主要发现
- 装置在全部患者中成功释放,除3例(1例择期、2例急诊)外所有目标血管均置入支架。
- 无30天死亡;随访平均25±13个月,发生10例晚期死亡(6例择期、4例急诊),均与装置或手术无关。
- 随访期间无破裂或转为开放修复。
- 2例发生肠缺血,1例保守治疗缓解,1例需肠系膜上动脉和腹腔干球囊扩张及支架置入。
- 肾动脉闭塞发生8例(11%),其中63%(5/8)被认为与手术相关,4例成功干预并保留肾功能。
关键数值与推荐
- 装置包括腹腔干凹槽、肠系膜上动脉开窗和两个锥形枢轴开窗以保留肾动脉血流。
- 装置有两种构型:左肾开窗与右肾开窗纵向位置相同(构型A)或更低(构型B)。
- 55%患者植入构型A,45%植入构型B。
临床怎么用
- 对于近肾腹主动脉瘤,即用型p-Branch开窗支架可作为可选治疗方案,但需注意肾动脉闭塞风险并加强术后监测。
局限性
- 数据来自四个单中心研究,样本量有限(76例),随访时间平均25±13个月,不足以评估长期耐久性。
- 研究包含学习曲线效应,可能影响早期结果的外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to report prospective data of an off-the-shelf fenestrated endograft (Zenith p-Branch; Cook Medical, Bloomington, Ind) from four centers for the treatment of patients with pararenal abdominal aortic aneurysms. METHODS: Data were combined from four single-center investigational studies conducted in the United States and Europe. The p-Branch endograft consists of a proximal off-the-shelf component incorporating a scallop for the celiac artery, a superior mesenteric artery fenestration, and two conical pivot fenestrations to preserve flow to the renal vessels. The device is available in two configurations, a left renal fenestration at the same (configuration A) or lower (configuration B) longitudinal position than the right to accommodate varied anatomy of the patients. RESULTS: Between August 2011 and September 2015, 76 patients (82% male; mean age, 72 years; 65 elective and 11 emergent) were enrolled, with 55% implanted with option A and 45% with B. The device was deployed successfully in all patients, and stents were placed in all target vessels except in three cases (one elective, two emergent): a left kidney was sacrificed in one patient, and a right renal artery was left unstented in two patients during the index procedure. There was no 30-day mortality. During follow-up (mean, 25 ± 13 months), 10 late deaths occurred (6 elective, 4 emergent; none related to device or procedure), and there were no ruptures or conversions to open repair. Two patients experienced bowel ischemia; one case resolved with nonoperative treatment and one required superior mesenteric artery and celiac artery angioplasty and stent placement. Renal artery occlusion occurred in eight patients (11%) and was deemed procedure related in 63% (5/8) of these patients. Four of these were successfully intervened on with preservation of renal function. The overall renal insufficiency incidence was 7% (5/76). One patient developed renal failure requiring dialysis. CONCLUSIONS: Early results incorporating learning curves for physicians with a new device and delivery system indicate that the use of the Zenith p-Branch device is feasible and safe. Long-term follow-up is needed to assess the effectiveness and durability of this treatment strategy and to refine the indications for use.
引用
- Farber MA, Eagleton MJ, Mastracci TM, et al. Results from multiple prospective single-center clinical trials of the off-the-shelf p-Branch fenestrated stent graft. J Vasc Surg. 2017. PMID: 28559176. doi:10.1016/j.jvs.2017.01.068
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。